90 likes | 213 Views
ONAMI’s - Safer Nanomaterials and Nanomanufacturing Initiative. Recommendations for the FDA Nanotechnology Task Force Stacey Harper. Issues for Nanotechnology. Potentially large-scale application (and thus large-scale impact)
E N D
ONAMI’s - Safer Nanomaterials and Nanomanufacturing Initiative Recommendations for the FDA Nanotechnology Task Force Stacey Harper
Issues for Nanotechnology Potentially large-scale application (and thus large-scale impact) • Trillion dollar industry by 2015 (NSF Report Societal Implications of • Nanoscience and Nanotechnology, 2001) Growing concerns about ecotoxicity, human health effects and safety • Chemistry and physics different at nanoscale size • Biological interactions largely unstudied • Lack of data: Impossible to assess risk without data Importance of public acceptance • Perceptual risks may be a barrier to commercialization • Activists already making the case that untested nanomaterials are being • forced on the public
Safer Nanomaterials and Nanomanufacturing Initiative (SNNI) Less wasteful nanomanufacturing Better, safer nanoparticles High performance nanodevices http://www.greennano.org/
Nanomaterialsynthesis TestProperties RedesignMaterial Structure/Property Relationships: Physicochemical properties and hazards Designing safer nanoparticles Nanoparticles have widely tunable properties - the key is to enhance performance and safety at the same time
Nanomaterial Effects Database Feed data back into design scheme Testing the biological impacts of engineered nanoparticles Tier 1: Toxicity Screening • Toxicity testing in cells, tissues and whole organisms • In vitro (human cells, tissue cultures) • In vivo (vertebrate models) Tier 2: Cellular Targets and Distribution • Defined in vivo • Fluorescent nanomaterials • Targeted assays Tier 3: Molecular Expression • Molecular (genetic) response • Whole animal gene expression profiles • Vertebrates eye heart
R = -CH2COO-Na+ -(CH2)2COOH -(CH2)11COOH -(CH2)2OH -(CH2)2PO(OH)2 -[(CH2)2O]2(CH2)2OH -(CH2)2O(CH2)2OH -[(CH2)2O]2CH2COOH -(CH2)2COGlyGlyOH -(CH2)2CONH(CH2)14CH3 -(CH2)17CH3 -(CH2)15CH3 -(CH2)11CH3 -(CH2)9CH3 -(CH2)8CH3 -(CH2)7CH3 -(CH2)5CH3 -(CH2)2CH3 -(CH2)2Si(OMe)3 • -(CH2)2SO3-Na+ • -(CH2)3SO3-Na+ • -(CH2)2N+HMe2Cl- • -(CH2)2N+Me3Cl- • (CH2)2O(CH2)2N+Me3-OTs • (CH2)2O(CH2) 2O(CH2)2 N+Me3-OTs • (CH2)2O(CH2) 2O(CH2)2 N+Et3-OTs Nanomaterialsynthesis RedesignMaterial TestProperties A diverse family of functionalized nanoparticles has been prepared for 1.5-nm and 0.8-nm core sizes
Negative Charge (2-mercaptoethanesulfonate) 0.8 nm Example: Toxicity affected by size and surface functionalization Positive Charge (N,N,N-trimethylammoniumethanethiol) 1.5 nm
Recommendations • Characterization and purification done carefully • Identify biological impacts • Identify environmental impacts • Incorporate toxicological evaluations into research and development schemes
Contact Information Jim Hutchison, PhD Director ONAMI Safer Nanomaterials and Nanomanufacturing Initiative hutch@uoregon.edu 541.346.4228 http://greenchem.uoregon.edu Bettye LS Maddux, PhD Assistant Director ONAMI Safer Nanomaterials and Nanomanufacturing Initiative bettye@greennano.org 541.713.1330 http://greennano.org/ Robert Tanguay, PhD Associate Professor Environmental and Molecular Toxicology Oregon State University robert.tanguay@oregonstate.edu 541.737.6514 http://emt.oregonstate.edu/faculty/tanguay.htm Stacey Lynn Harper, PhD NIEHS Research Fellow Environmental Health Sciences Center Oregon State University harpers@science.oregonstate.edu 541.737.2791 http://www.onami.us/NanoNet/researchers